CEO Clive Dix spoke to Proactive Investors on today’s business update.
Talking about the collaboration with the GEN-COVID Consortium in Italy, Clive said "The disease continues to spread throughout the world and a clear understanding of how it affects people differently remains elusive. We believe that genetics may play a role in explaining the differences in an individual's disease susceptibility, severity and prognosis."
The criticality of venturing into new drugs has been discussed in the earlier segment, and an encouraging step has been taken in this direction. C4X Discovery (C4XD), a leading UK-based drug discovery company which develops new drug combinations for chronic addiction and cancer is credited to create its own VR tool named, 4Sight...
Clive Dix talks Proactive London's Andrew Scott through its interim results to January 2020.
Dix says its NRF-2 activator programme for sickle cell disease and pulmonary arterial hypertension is progressing and it is down to a short-list of three molecules.
Dr Clive Dix, Chief Executive Officer, and members of the management team host this live presentation for analysts - watch this on-demand replay.
Clive Dix speaks to Proactive London's Andrew Scott following the news they've raised around £6.6mln to strengthen its balance sheet amid ongoing licensing discussions for its early-stage drug candidates.
Clive Dix updates Proactive London's Andrew Scott on progress across the firm's portfolio.
He says they're very confident of delivering deals in the near future.
At least one biotechnology company that develops new drugs for a living has created its own virtual reality platform for drug discovery. Founded in 2007, C4X Discovery (C4XD) out of Manchester, England, is a small-cap public company that has developed its own VR platform called 4Sight.